Evaluating PET/CT Imaging for Advanced Colorectal Cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study investigates the effectiveness of 18F-FDG and 68Ga-FAPI PET/CT imaging in assessing the outcomes of conversion therapy for patients with advanced colorectal cancer, particularly those with peritoneal metastasis. Participants will undergo imaging at baseline and again after three months of therapy, with results compared to histopathological and clinical assessments. The goal is to determine the prognostic value of these imaging techniques in this patient population.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Histologically confirmed colorectal cancer, clinical or other imaging suspicion of peritoneal metastasis with or without other distant metastases.
2. Patients voluntarily enrolled in this study by signing an informed consent form
3. Age ≥ 18 years
4. Expected life expectancy ≥ 3 months
5. Adequate organ and bone marrow function
6. Willingness to adhere to the study protocol and follow-up programme

Exclusion Criteria:

1. Pregnant or breastfeeding women.
2. Patients with a history of other malignant diseases in the last 5 years, except cured skin cancer and carcinoma in situ of cervix
3. Severe mental disease, uncontrolled epilepsy, or central nervous system disease
4. Subjects with current concurrent interstitial pneumonitis or interstitial lung disease, or subjects with previous interstitial pneumonitis or interstitial lung disease requiring hormonal therapy, or subjects with other conditions that may interfere with the judgement and management of immune-related pulmonary toxicity, e.g., pulmonary fibrosis, organising pneumonia (e.g., occlusive bronchiectasis), pulmonary fibrosis, organising pneumonia (e.g., occlusive bronchiectasis), pneumoconiosis, Drug-associated pneumonia, idiopathic pneumonia, active pneumonia, or severe pulmonary impairment on CT; and active tuberculosis

Where it's running

• Ruijin Hospital affiliated to Shanghai Jiao Tong University of Medicine
  Shanghai, Shanghai Municipality, China Recruiting

Study contacts

• Study coordinator: Jiajia Hu
• Email: jiajiahu@shsmu.edu.cn
• Phone: 13524945287

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• SHR-A1811 plus chemotherapy and bevacizumab as first-line treatment for advanced colorectal cancer

  A first-line treatment test combines SHR-A1811 with chemotherapy and bevacizumab to see if it works better than standard therapy in adults with advanced colorectal cancer.

  Recruiting Phase 3 Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Beijing, Beijing Municipality · NCT07676162

• Following therapy response with a blood test (liquid biopsy) in metastatic colorectal cancer

  This trial tests whether using a blood test that measures NPY-methylation ctDNA to guide treatment decisions helps people with unresectable metastatic colorectal cancer who are starting first-line therapy.

  Recruiting at 9 sites Phase 3 University Hospital, Antwerp · Mechelen, Antwerpen and 8 other locations · NCT07558083

• First-line treatment of advanced colorectal cancer using simultaneous levofolinate and 5‑FU infusion

  This trial will try combining simultaneous infusion of levofolinate (levozolinate) with 5‑FU as first-line chemotherapy for adults with unresectable or metastatic colorectal cancer.

  Recruiting Phase 2 Chinese PLA General Hospital · Beijing · NCT07391618

• CBI-1214 T-cell engager for advanced MSS/MSI-L colorectal cancer

  This trial will test whether the experimental T-cell engager CBI-1214 is safe, reaches appropriate blood levels, and can shrink tumors in people with advanced or metastatic MSS/MSI-L colorectal cancer who have had prior treatment.

  Recruiting at 10 sites Phase 1 Cartography Biosciences · Phoenix, Arizona and 9 other locations · NCT07321106

• Second-line therapy with Ongericimab and Toripalimab plus bevacizumab and chemotherapy in advanced MSS/pMMR colorectal cancer

  This study tests a second-line treatment that combines Ongericimab and Toripalimab with bevacizumab and chemotherapy for adults with advanced MSS/pMMR colorectal cancer who have progressed after first-line therapy.

  Recruiting Phase 2 Shanghai Pudong Hospital · Shanghai, Shanghai Municipality · NCT07106034

• JS207 with or without JS015 plus XELOX chemotherapy for advanced colorectal cancer

  This study will test whether adding the new drug JS207, alone or with JS015, to standard XELOX chemotherapy helps people with advanced MSS/pMMR colorectal cancer respond better or live longer.

  Recruiting at 2 sites Phase 2 Shanghai Junshi Bioscience Co., Ltd. · Beijing, Beijing Municipality and 1 other locations · NCT06885385

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.